electroCore, Inc.
Change company Symbol lookup
Select an option...
ECOR electroCore, Inc.
NXPI NXP Semiconductors NV
PRTK Paratek Pharmaceuticals Inc
VTR Ventas Inc
GBIM Globeimmune Inc
SCKT Socket Mobile Inc
BK Bank of New York Mellon Corp
BAC Bank of America Corp
AACG ATA Creativity Global
MDXL Medixall Group Inc
Go

Company profile

ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.

Price
Delayed
$1.74
Day's Change
-0.04 (-2.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.78
Day's Low
1.66
Volume
(Light)

Today's volume of 115,199 shares is on pace to be much lighter than ECOR's 10-day average volume of 444,650 shares.

115,199

Company Profile

ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
27.86x
Price/Book (MRQ)
3.30x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2020
Current Month
945.2K
Previous Month
896.4K
Percent of Float
2.71%
Days to Cover
1.6542 Days

Share Information

ECOR is in a share class of common stock
Float
35.0M
Shares Outstanding
44.5M
Institutions Holding Shares
43
12.86%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Michael G. AtiehChmn.
  • Daniel S. GoldbergerCEO
  • Brian M. PosnerCFO
  • Mike RomaniwExec.VP
  • Eric J. LieblerSr.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.